



Lentigen™

NEWS RELEASE

LENTIGEN CORPORATION AND EVROGEN JSC ENTER LICENSE AGREEMENT FOR NOVEL FLUORESCENT PROTEIN TECHNOLOGY

Baltimore, Maryland and Moscow, Russia January 30, 2006 – Lentigen Corporation and Evrogen JSC announced today a licensing agreement whereby Lentigen will obtain access to certain novel fluorescent protein technologies. Such technologies will enable the Company to expand customer service opportunities related to the design and manufacturing of its proprietary lentiviral vectors. Access to these fluorescent technologies, including TurboGFP (green fluorescent protein), phi YFP (yellow) and J-Red (Red) will allow Lentigen to create lentiviral vectors with a multiple of fluorescent possibilities for customers who purchase its custom lentiviral vectors. No financial terms of the agreement were disclosed.

“This license agreement represents another important offering for Lentigen customers,” remarked Dr. Boro Dropulic, Founder and CEO of Lentigen. “These technologies expand the opportunities now available to Lentigen and our customers by providing additional research capabilities to our lentiviral vector technology. Lentigen aims to license additional technologies which add to the usefulness of our lentiviral vectors for both research and therapeutic purposes.”

Dr. Sergey Lukyanov, Evrogen’s Chief Scientific Officer, said: “We are pleased to have established the license agreement and collaboration with Lentigen Corporation to further expand the adoption and availability of novel fluorescent protein technology for life science researchers interested in new lentiviral products and related services.”

About Lentiviral Vectors

Lentiviral vectors (LV) are vehicles that can deliver genes or RNAi into cells with up to 100% efficiency and stability. By comparison, other viral vector systems such as non-viral, adenoviral and adeno-associated viral vectors have not been shown to achieve both high and stable gene delivery in dividing cells.

Gene delivery is accomplished by the binding and fusing of the LV pseudotyped envelope protein to the target cell membrane. The LV RNA containing the gene or gene silencing sequence is then incorporated into the cell via reverse transcription creating a DNA complex. This complex enters the nucleus incorporating into the chromosomal DNA creating a stable molecule. The gene sequence is integrated in the chromosome and is copied along with the DNA during ongoing cell division.

About Lentigen Corporation

Lentigen Corporation is a privately owned biotechnology company focused on the manufacturing and development of lentiviral vectors using its proprietary gene delivery technology for a wide range of applications in biotechnology and medicine. Lentiviral vectors are highly adapted delivery vehicles that can transport genes or gene silencing sequences into cells with high efficiency and stability. Lentigen is positioning itself to become the leading provider of Lentiviral vector products and services for academic, government, biotechnology and pharmaceutical researchers. For further information, visit www.Lentigen.com.

About Evrogen JCS

Evrogen is an innovative biotechnology company committed to provide products and services for scientists involved in gene discovery and analysis. Evrogen is inspired to contribute innovations and its extensive experience in life sciences to the international research community.

Contacts:

Lentigen Corporation
Greg Feulner, VP Business Development
443-543-5318
greg.feulner@lentigen.com

Evrogen JCS
Timofei Panfilov, Director
Tel.: (+7 095) 429 80 20
timofei@evrogen.com

Media Contact:

Gregory Tiberend
Richard Lewis Communications, Inc.
212-827-0020
gtiberend@rlcinc.com

Investor Contact:

Tara Spiess
TS Communications Group, LLC
914-921-5900
spiess@biotechirpr.com